Active immunization with extracellular vesicles derived from Staphylococcus aureus effectively protects against staphylococcal lung infections, mainly via Th1 cell-mediated immunity

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Choi, Seng Jin ^a   Kim, Min Hye ^b   Jeon, Jinseong ^a   Kim, Oh Youn ^a   Choi, Youngwoo ^a   Seo, Jihye ^a   Hong, Sung Wook ^a,c   Lee, Won Hee ^a   Jeon, Seong Gyu ^a   Gho, Yong Song ^a   Jee, Young Koo ^d   Kim, Yoon Keun ^b  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Institute for Basic Science   (South Korea)

^d Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; STAPHYLOCOCCUS VACCINE; TOLL LIKE RECEPTOR;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL VIABILITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EX VIVO STUDY; EXOSOME; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; LETHALITY; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOLOGY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; LUNG; MICROBIOLOGY; PNEUMONIA; STAPHYLOCOCCAL INFECTIONS; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INTERLEUKIN-17; LUNG; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; PNEUMONIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TH1 CELLS; TOLL-LIKE RECEPTORS; VACCINATION;

EID: 84947461405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136021     Document Type: Article

References (49)

1. Kluytmans J, van Belkum A, Verbrugh H (1997) Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10: 505-520. PMID: 9227864
2. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339: 520-532. PMID: 9709046
3. Richards MJ, Edwards JR, Culver DH, Gaynes RP (2000) Nosocomial infections in combined medicalsurgical intensive care units in the United States. Infect Control Hosp Epidemiol 21: 510-515. PMID: 10968716
4. David MZ, Daum RS (2010) Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23: 616-687. doi: 10.1128/CMR.00081-09 PMID: 20610826
5. Levine MM, Sztein MB (2004) Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5: 460-464. PMID: 15116108
6. Fearon DT, Locksley RM (1996) The instructive role of innate immunity in the acquired immune response. Science 272: 50-53. PMID: 8600536
7. Lee EY, Bang JY, Park GW, Choi DS, Kang JS, Kim HJ, et al. (2007) Global proteomic profiling of native outer membrane vesicles derived from Escherichia coli. Proteomics 7: 3143-3153. PMID: 17787032
8. Bomberger JM, Maceachran DP, Coutermarsh BA, Ye S, O'Toole GA, Stanton BA, et al. (2009) Longdistance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog 5: e1000382. doi: 10.1371/journal.ppat.1000382 PMID: 19360133
9. Kwon SO, Gho YS, Lee JC, Kim SI (2009) Proteome analysis of outer membrane vesicles from a clinical Acinetobacter baumannii isolate. FEMS Microbiol Lett 297: 150-156. doi: 10.1111/j.1574-6968.2009.01669.x PMID: 19548894
10. Kim OY, Hong BS, Park KS, Yoon YJ, Choi SJ, Lee WH, et al. (2013) Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol 190: 4092-4102. doi: 10.4049/jimmunol.1200742 PMID: 23514742
11. Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, et al. (2009) Gram-positive bacteria produce membrane vesicles: proteomics-based characterization of Staphylococcus aureus-derived membrane vesicles. Proteomics 9: 5425-5436. doi: 10.1002/pmic.200900338 PMID: 19834908
12. Hong SW, Kim MR, Lee EY, Kim JH, Kim YS, Jeon SG, et al. (2011) Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation. Allergy 66: 351-359. doi: 10.1111/j.1398-9995.2010.02483.x PMID: 20831718
13. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811. PMID: 10837075
14. Bubeck Wardenburg J, Schneewind O (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294. doi: 10.1084/jem.20072208 PMID: 18268041
15. Cook J, Hepler R, Pancari G, Kuklin N, Fan H, Wang WM, et al. (2009) Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection. Hum Vaccin 5: 254-263. PMID: 18787395
16. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO (2008) Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 76: 5738-5744. doi: 10.1128/IAI.00874-08 PMID: 18809660
17. Stranger-Jones YK, Bae T, Schneewind O (2006) Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103: 16942-16947. PMID: 17075065
18. Kim HK, Kim HY, Schneewind O, Missiakas D (2011) Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J 25: 3605-3612. doi: 10.1096/fj.11-187963 PMID: 21753082
19. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD, et al. (2008) Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 198: 571-575. doi: 10.1086/590210 PMID: 18613794
20. Spellberg B, Daum R (2012) Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 34: 335-348. doi: 10.1007/s00281-011-0293-5 PMID: 22080194
21. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796. doi: 10.1038/nri2868 PMID: 20948547
22. Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A (2004) Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J 147: 593-598. PMID: 15077073
23. Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, et al. (2012) The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. Vaccine 30: 1729-1736. doi: 10.1016/j.vaccine.2011.12.045 PMID: 22192849
24. Bagnoli F, Bertholet S, Grandi G (2012) Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2: 16. doi: 10.3389/fcimb.2012.00016 PMID: 22919608
25. O'Riordan K, Lee JC (2004) Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 17: 218-234. PMID: 14726462
26. Schaffer AC, Lee JC (2008) Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 32 Suppl 1: S71-78. doi: 10.1016/j.ijantimicag.2008.06.009 PMID: 18757184
27. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, et al. (2006) A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74: 2215-2223. PMID: 16552052
28. Ohlsen K, Lorenz U (2010) Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol 300: 402-410. doi: 10.1016/j.ijmm.2010.04.015 PMID: 20547101
29. Otto M (2010) Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther 10: 1049-1059. doi: 10.1517/14712598.2010.495115 PMID: 20528609
30. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572-1580. PMID: 11740733
31. Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, et al. (2006) Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50: 511-518. PMID: 16436704
32. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Kaufman D, et al. (2007) Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151: 260-265, 265 e261. PMID: 17719934
33. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, et al. (2005) Kaufman Dand in acutely infected patients. Clin Diagn Lab Immunol 12: 387-398
34. Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SA, Stapleton MR, et al. (2006) Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193: 1098-1108. PMID: 16544250
35. Verkaik NJ, de Vogel CP, Boelens HA, Grumann D, Hoogenboezem T, Vink C, et al. (2009) Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J Infect Dis 199: 625-632. doi: 10.1086/596743 PMID: 19199541
36. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, et al. (2008) The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 76: 4574-4580. doi: 10.1128/IAI.00700-08 PMID: 18644876
37. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. (2010) IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120: 1762-1773. doi: 10.1172/JCI40891 PMID: 20364087
38. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5: e1000703. doi: 10.1371/journal.ppat.1000703 PMID: 20041174
39. Edwards SW, Say JE, Hart CA (1987) Oxygen-dependent killing of Staphylococcus aureus by human neutrophils. J Gen Microbiol 133: 3591-3597. PMID: 2846751
40. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. (2009) Fast rise of broadly crossreactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106: 7962-7967. doi: 10.1073/pnas.0903181106 PMID: 19416838
41. Jones T (2009) GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection. Curr Opin Mol Ther 11: 337-345. PMID: 19479667
42. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, et al. (2011) Influenza vaccine immunology. Immunol Rev 239: 167-177. doi: 10.1111/j.1600-065X.2010.00974.x PMID: 21198671
43. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, et al. (2009) MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 26: 1477-1485. doi: 10.1007/s11095-009-9859-5 PMID: 19255727
44. Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, et al. (2008) Adult-like antimycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85BS-ESAT-6 in the IC31 adjuvant. PLoS One 3: e3683. doi: 10.1371/journal.pone.0003683 PMID: 18997860
45. Kim MR, Hong SW, Choi EB, Lee WH, Kim YS, Jeon SG, et al. (2012) Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses. Allergy 67: 1271-1281. doi: 10.1111/all.12001 PMID: 22913540
46. Lin HY, Tang CH, Chen YH, Wei IH, Chen JH, Lai CH, et al. (2010) Peptidoglycan enhances proinflammatory cytokine expression through the TLR2 receptor, MyD88, phosphatidylinositol 3-kinase/AKT and NF-kappaB pathways in BV-2 microglia. Int Immunopharmacol 10: 883-891. doi: 10.1016/j.intimp.2010.04.026 PMID: 20451669
47. Lee IT, Lee CW, Tung WH, Wang SW, Lin CC, Shu JC, et al. (2010) Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am J Pathol 176: 1671-1684. doi: 10.2353/ajpath.2010.090714 PMID: 20167866
48. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655. PMID: 1303622
49. Park KS, Choi KH, Kim YS, Hong BS, Kim OY, Kim JH, et al. (2010) Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. PLoS One 5: e11334. doi: 10.1371/journal.pone.0011334 PMID: 20596524